Generated Narrative: CodeSystem v3-substanceAdminSubstitution Language: en Properties This code system defines the following properties for its concepts Name Code URI Type Description Specializes Specializes Coding The child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric. Generalizes Generalizes Coding Inverse of Specializes. Only included as a derived relationship. internalId internalId http://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-id code The internal identifier for the concept in the HL7 Access database repository. Not Selectable notSelectable http://hl7.org/fhir/concept-properties#notSelectable boolean Indicates that the code is abstract - only intended to be used as a selector for other concepts Status status http://hl7.org/fhir/concept-properties#status code Designation of a concept's state. Normally is not populated unless the state is retired. Concepts This case-sensitive code system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution defines the following codes in a Is-A hierarchy: Lvl Code Display Definition internalId Not Selectable Status 1 _ActSubstanceAdminSubstitutionCode ActSubstanceAdminSubstitutionCode Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. 21284 true active 2 E equivalent Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. 23107 active 3 EC equivalent composition Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril 23108 active 4 BC brand composition Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven 23109 active 4 G generic composition Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) 16623 active 3 TE therapeutic alternative Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet 16624 active 4 TB therapeutic brand Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics Examples: Zantac for Tagamet 23105 active 4 TG therapeutic generic Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands Examples: Ranitidine for cimetidine 23106 active 2 F formulary This substitution was performed or is permitted based on formulary guidelines. 16625 active 2 N none No substitution occurred or is permitted. 16622 active
Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.
This material derives from the HL7 Terminology THO. THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html
The child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric.
Inverse of Specializes. Only included as a derived relationship.
The internal identifier for the concept in the HL7 Access database repository.
Indicates that the code is abstract - only intended to be used as a selector for other concepts
Designation of a concept's state. Normally is not populated unless the state is retired.
Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
Substitution occurred or is permitted with another product that is a: * pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester * pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration *Examples:* * *Pharmaceutical alternative:* Erythromycin Ethylsuccinate for Erythromycin Stearate * *Pharmaceutical equivalent:* Lisonpril for Zestril
Substitution occurred or is permitted between equivalent Brands but not Generics *Examples:* * Zestril for Prinivil * Coumadin for Jantoven
Substitution occurred or is permitted between equivalent Generics but not Brands *Examples:* * Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. *Examples:* * ranitidine for Tagamet
Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > *Examples:* * Zantac for Tagamet
Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > *Examples:* * Ranitidine for cimetidine
This substitution was performed or is permitted based on formulary guidelines.
No substitution occurred or is permitted.